Skip to content

Application of deep muscle release without intubation anesthesia supported by nasal high flow in fiberoptic bronchoscopy of patients with pulmonary tuberculosis

Application of deep muscle release without intubation anesthesia supported by nasal high flow in fiberoptic bronchoscopy of patients with pulmonary tuberculosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093382
Enrollment
Unknown
Registered
2024-12-03
Start date
2024-12-03
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

experimental group :deep muscle release without intubation anesthesia supported by nasal high flow
control group:traditional intravenous anesthesia

Sponsors

The Second Hospital of Nanjing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Pulmonary tuberculosis patients undergoing routine tracheoscopy; Gender is not limited; 18 years old <= age <=65 years old; BMI 18.5~23.9 kg/m2; ASA I~? grade; Informed consent, voluntary participation in the experiment, and the informed consent signed by the patient, approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: If the examination time is expected to exceed 15min, if the operation is complicated or the tracheoscopy diagnosis and treatment technology is required, the laser or electrotome is required, or the blood loss is expected to be large; After full communication with the tuberculosis doctor, it is considered that the patient (intraoperative treatment may be added, etc.) is not suitable for this clinical study; Complicated with intracranial nervous system disease, intracranial hypertension, complicated with neuromuscular disease, etc.; Patients with severe communication disorders caused by severe hearing degradation; Acute or severe respiratory disease, cardiovascular disease, including but not limited to recent upper respiratory tract infection, severe or extremely severe chronic obstructive ventilation dysfunction, asthma (airway hyperresponsiveness), refractory hypoxemia, intolerance of hypercarbon dioxide, heart failure, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.; Patients with a full stomach, or with severe gastroesophageal reflux and other diseases with a high risk of aspiration; Difficult airway; Allergy to narcotic drugs; The patient refused.

Design outcomes

Primary

MeasureTime frame
Incidence of hypoxemia;Arterial blood gas tests;

Secondary

MeasureTime frame
Success rate of anesthesia;Induction time of anesthesia;Occupy operating room time;Anesthesia recovery time;Incidence of pharyngialgia;

Countries

China

Contacts

Public ContactXie Dongming

The Second Hospital of Nanjing

120600232@qq.com+86 157 5187 0289

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026